

Is Citric Acid/Potassium Citrate in shortage in 2026? Get the latest update on availability, costs, and what patients can do right now.
If you've been told your pharmacy doesn't have Citric Acid/Potassium Citrate in stock, you're probably wondering: is there a shortage? The short answer is complicated. While there isn't a formally declared national shortage as of early 2026, many patients are still running into trouble filling their prescriptions.
In this update, we'll break down the current availability picture, explain why it's been hard to find, discuss what it costs in 2026, and lay out your options for getting the medication you need.
As of March 2026, Citric Acid/Potassium Citrate oral solution is not listed on the FDA Drug Shortage Database. This means the FDA has not declared a formal shortage.
However, that doesn't tell the whole story. The FDA shortage list only captures medications where manufacturers have reported supply disruptions. Localized shortages — where specific pharmacies or regions run out — don't always make the list.
What patients are experiencing on the ground:
So while it's not officially in shortage, it can certainly feel like one when your pharmacy can't get it.
Several factors have contributed to availability issues:
Only a handful of companies produce Citric Acid/Potassium Citrate oral solution, including PAI Pharma, Chartwell RX, and Pharmaceutical Associates. With so few manufacturers, any single production issue can create a ripple effect that patients feel immediately.
Kidney stones are becoming more common in the United States. Research shows that roughly 1 in 10 Americans will develop a kidney stone at some point, and rates have been climbing steadily. As more people are prescribed urinary alkalinizers, the demand for medications like Citric Acid/Potassium Citrate grows.
Global supply chain issues have affected pharmaceutical manufacturing broadly. Raw material sourcing, quality control requirements, and shipping logistics all play a role in how quickly manufacturers can get product to pharmacy shelves.
Large pharmacy chains use automated inventory systems that prioritize high-volume medications. Because Citric Acid/Potassium Citrate is somewhat niche compared to drugs like Lisinopril or Metformin, it may not be kept in stock at every location.
For a deeper dive into why this happens, read our article on why Citric Acid/Potassium Citrate is so hard to find.
Here's what you can expect to pay:
The generic version is widely available and works identically to the brand-name products. There's rarely a medical reason to pay more for a brand.
For all the ways to lower your cost, check out our full guide on how to save money on Citric Acid/Potassium Citrate.
While no brand-new formulations of Citric Acid/Potassium Citrate have launched recently, patients do have more tools and options than ever:
For a full breakdown of your alternatives, see alternatives to Citric Acid/Potassium Citrate.
Here's your action plan:
For detailed tips, read our guide on how to find Citric Acid/Potassium Citrate in stock near you.
The availability picture for Citric Acid/Potassium Citrate in 2026 isn't perfect, but it's manageable. The medication is not in a formal FDA-declared shortage, and generic versions remain available from multiple manufacturers. The challenge is usually about finding the right pharmacy at the right time.
Use Medfinder to cut through the frustration, explore your alternatives, and stay in close contact with your doctor. Managing kidney stones or metabolic acidosis is a long game — and having a reliable plan for getting your medication is part of winning it.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.